PubRank

Leonidas C Platanias

Author PubWeight™ 182.45‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012 20.08
2 Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required for hypoxia signaling. Mol Cell Biol 2005 1.97
3 Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood 2008 1.95
4 Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proc Natl Acad Sci U S A 2008 1.81
5 Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci U S A 2010 1.75
6 Protein kinase C-delta (PKC-delta ) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J Biol Chem 2002 1.72
7 Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J Biol Chem 2001 1.71
8 Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood 2012 1.66
9 AMPK as a therapeutic target in renal cell carcinoma. Cancer Biol Ther 2010 1.66
10 Interferons: mechanisms of action and clinical applications. Curr Opin Oncol 2003 1.56
11 Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. Leuk Lymphoma 2009 1.53
12 Jak family of kinases in cancer. Cancer Metastasis Rev 2003 1.52
13 Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-beta1-induced pericellular collagenolysis. J Biol Chem 2004 1.49
14 Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood 2006 1.48
15 MEKK1 plays a critical role in activating the transcription factor C/EBP-beta-dependent gene expression in response to IFN-gamma. Proc Natl Acad Sci U S A 2002 1.47
16 Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J Immunol 2002 1.41
17 Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. J Biol Chem 2006 1.41
18 Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res 2005 1.40
19 Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J Biol Chem 2003 1.36
20 Statins in tumor suppression. Cancer Lett 2008 1.34
21 Phosphorylation of forkhead transcription factors by erythropoietin and stem cell factor prevents acetylation and their interaction with coactivator p300 in erythroid progenitor cells. Oncogene 2002 1.32
22 Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res 2006 1.31
23 Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res 2011 1.29
24 The interferon consensus sequence-binding protein activates transcription of the gene encoding neurofibromin 1. J Biol Chem 2004 1.29
25 Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther 2008 1.28
26 AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood 2013 1.26
27 Targeting mTOR for the treatment of AML. New agents and new directions. Oncotarget 2011 1.26
28 Interferon-gamma engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein. Exp Cell Res 2004 1.25
29 Activation of protein kinase C delta by IFN-gamma. J Immunol 2003 1.25
30 The p38 mitogen-activated protein kinase pathway in interferon signal transduction. J Interferon Cytokine Res 2005 1.23
31 Role of p38alpha Map kinase in Type I interferon signaling. J Biol Chem 2003 1.23
32 Dual regulatory roles of phosphatidylinositol 3-kinase in IFN signaling. J Immunol 2008 1.22
33 Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway. J Biol Chem 2008 1.21
34 Interferon-dependent engagement of eukaryotic initiation factor 4B via S6 kinase (S6K)- and ribosomal protein S6K-mediated signals. Mol Cell Biol 2009 1.21
35 Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res 2007 1.20
36 Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts. Arthritis Rheum 2004 1.19
37 Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide. J Biol Chem 2010 1.17
38 Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J Biol Chem 2002 1.17
39 Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses. Proc Natl Acad Sci U S A 2009 1.17
40 The PI3' kinase pathway in interferon signaling. J Interferon Cytokine Res 2005 1.17
41 Cross-talk between NFkB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis. PLoS One 2012 1.17
42 Role of Schlafen 2 (SLFN2) in the generation of interferon alpha-induced growth inhibitory responses. J Biol Chem 2009 1.14
43 Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha. Proc Natl Acad Sci U S A 2003 1.14
44 Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors. Blood 2013 1.13
45 Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma. Clin Cancer Res 2008 1.13
46 Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes. Cancer Res 2005 1.13
47 AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival. Biochem Biophys Res Commun 2010 1.12
48 Role of interferon {alpha} (IFN{alpha})-inducible Schlafen-5 in regulation of anchorage-independent growth and invasion of malignant melanoma cells. J Biol Chem 2010 1.12
49 Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. Leuk Lymphoma 2008 1.11
50 Activation of the mitogen- and stress-activated kinase 1 by arsenic trioxide. J Biol Chem 2006 1.11
51 Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses. J Biol Chem 2007 1.11
52 Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res 2010 1.10
53 Engagement of protein kinase C-theta in interferon signaling in T-cells. J Biol Chem 2004 1.10
54 Protein kinase C-delta and phosphatidylinositol 3-kinase/Akt activate mammalian target of rapamycin to modulate NF-kappaB activation and intercellular adhesion molecule-1 (ICAM-1) expression in endothelial cells. J Biol Chem 2008 1.08
55 Activation of protein kinase C delta by all-trans-retinoic acid. J Biol Chem 2003 1.06
56 Sanguinarine-dependent induction of apoptosis in primary effusion lymphoma cells. Cancer Res 2007 1.06
57 Vaccinia virus activation of CCR5 invokes tyrosine phosphorylation signaling events that support virus replication. J Virol 2006 1.04
58 Mechanisms of type-I interferon signal transduction. J Biochem Mol Biol 2004 1.04
59 All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma. Br J Haematol 2010 1.04
60 8-Amino-adenosine induces loss of phosphorylation of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2, and Akt kinase: role in induction of apoptosis in multiple myeloma. Mol Cancer Ther 2005 1.04
61 Regulatory effects of mTORC2 complexes in type I IFN signaling and in the generation of IFN responses. Proc Natl Acad Sci U S A 2012 1.03
62 Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood 2005 1.03
63 Interferon consensus sequence binding protein (ICSBP) decreases beta-catenin activity in myeloid cells by repressing GAS2 transcription. Mol Cell Biol 2010 1.02
64 Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. J Biol Chem 2004 1.02
65 AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications. Oncotarget 2011 1.02
66 Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2. J Biol Chem 2008 1.02
67 HoxA10 regulates transcription of the gene encoding transforming growth factor beta2 (TGFbeta2) in myeloid cells. J Biol Chem 2010 1.01
68 Targeting AMPK in the treatment of malignancies. J Cell Biochem 2012 1.00
69 CCL5-mediated T-cell chemotaxis involves the initiation of mRNA translation through mTOR/4E-BP1. Blood 2008 1.00
70 Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma. Oncogene 2005 0.99
71 The schlafen family of proteins and their regulation by interferons. J Interferon Cytokine Res 2013 0.99
72 Exploiting the mammalian target of rapamycin pathway in hematologic malignancies. Curr Opin Hematol 2008 0.99
73 Essential role for Mnk kinases in type II interferon (IFNgamma) signaling and its suppressive effects on normal hematopoiesis. J Biol Chem 2010 0.99
74 p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion. Oncogene 2003 0.99
75 The protein kinase C (PKC) family of proteins in cytokine signaling in hematopoiesis. J Interferon Cytokine Res 2007 0.98
76 Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma. Leuk Lymphoma 2009 0.98
77 Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. J Biol Chem 2011 0.97
78 c-Src interacts with and phosphorylates RelA/p65 to promote thrombin-induced ICAM-1 expression in endothelial cells. Am J Physiol Lung Cell Mol Physiol 2006 0.97
79 Mechanisms of mRNA translation of interferon stimulated genes. Cytokine 2010 0.97
80 Antileukemic effects of AMPK activators on BCR-ABL-expressing cells. Blood 2011 0.96
81 Role of Stat5 in type I interferon-signaling and transcriptional regulation. Biochem Biophys Res Commun 2003 0.96
82 α6β4 integrin, a master regulator of expression of integrins in human keratinocytes. J Biol Chem 2012 0.95
83 An overview of the mTOR pathway as a target in cancer therapy. Expert Opin Ther Targets 2012 0.95
84 Role of protein kinase C-delta (PKC-delta) in the generation of the effects of IFN-alpha in chronic myelogenous leukemia cells. Exp Hematol 2005 0.94
85 Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies. Curr Opin Oncol 2011 0.93
86 EVI1 abrogates interferon-alpha response by selectively blocking PML induction. J Biol Chem 2004 0.93
87 Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 2004 0.92
88 Negative regulatory effects of Mnk kinases in the generation of chemotherapy-induced antileukemic responses. Mol Pharmacol 2010 0.92
89 A role for mixed lineage kinases in regulating transcription factor CCAAT/enhancer-binding protein-{beta}-dependent gene expression in response to interferon-{gamma}. J Biol Chem 2005 0.92
90 Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting. Clin Cancer Res 2014 0.92
91 Inhibition of phosphatidylinositol 3'-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway. Biochem Biophys Res Commun 2004 0.91
92 TGF-β/Smad3 activates mammalian target of rapamycin complex-1 to promote collagen production by increasing HIF-1α expression. Am J Physiol Renal Physiol 2013 0.91
93 Regulatory effects of programmed cell death 4 (PDCD4) protein in interferon (IFN)-stimulated gene expression and generation of type I IFN responses. Mol Cell Biol 2012 0.90
94 Sprouty proteins are negative regulators of interferon (IFN) signaling and IFN-inducible biological responses. J Biol Chem 2012 0.90
95 HoxA10 protein regulates transcription of gene encoding fibroblast growth factor 2 (FGF2) in myeloid cells. J Biol Chem 2012 0.89
96 Regulation of the kinase RSK1 by arsenic trioxide and generation of antileukemic responses. Cancer Biol Ther 2013 0.89
97 Protein kinase R as mediator of the effects of interferon (IFN) gamma and tumor necrosis factor (TNF) alpha on normal and dysplastic hematopoiesis. J Biol Chem 2011 0.89
98 Activation of protein kinase C{eta} by type I interferons. J Biol Chem 2009 0.88
99 Interferon-alpha/beta-receptor interactions: a complex story unfolding. Curr Pharm Des 2002 0.88
100 Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells. Mol Cancer Ther 2006 0.88
101 Regulatory effects of ribosomal S6 kinase 1 (RSK1) in IFNλ signaling. J Biol Chem 2010 0.87
102 Calcium-induced matrix metalloproteinase 9 gene expression is differentially regulated by ERK1/2 and p38 MAPK in oral keratinocytes and oral squamous cell carcinoma. J Biol Chem 2004 0.87
103 Growth suppressive cytokines and the AKT/mTOR pathway. Cytokine 2009 0.87
104 Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells. J Biol Chem 2008 0.87
105 Thymoquinone suppresses growth and induces apoptosis via generation of reactive oxygen species in primary effusion lymphoma. Free Radic Biol Med 2011 0.86
106 Akt and mRNA translation by interferons. Cell Cycle 2008 0.86
107 Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer. Expert Opin Investig Drugs 2013 0.86
108 Activation of mitogen-activated protein kinase kinase (MKK) 3 and MKK6 by type I interferons. J Biol Chem 2005 0.85
109 The CrkL adapter protein is required for type I interferon-dependent gene transcription and activation of the small G-protein Rap1. Biochem Biophys Res Commun 2002 0.84
110 Philadelphia chromosome positive acute myeloid leukemia or de novo chronic myeloid leukemia-blast phase? Leuk Lymphoma 2013 0.84
111 Essential role for the Mnk pathway in the inhibitory effects of type I interferons on myeloproliferative neoplasm (MPN) precursors. J Biol Chem 2013 0.84
112 Proteasome inhibitor MG-132 mediated expression of p27Kip1 via S-phase kinase protein 2 degradation induces cell cycle coupled apoptosis in primary effusion lymphoma cells. Leuk Lymphoma 2009 0.84
113 Signalling pathways activated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Leuk Lymphoma 2004 0.84
114 Critical roles for Rictor/Sin1 complexes in interferon-dependent gene transcription and generation of antiproliferative responses. J Biol Chem 2014 0.84
115 Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL. Leuk Lymphoma 2011 0.84
116 The leukemia-associated Mll-Ell oncoprotein induces fibroblast growth factor 2 (Fgf2)-dependent cytokine hypersensitivity in myeloid progenitor cells. J Biol Chem 2013 0.83
117 Mechanisms of type I interferon signaling in normal and malignant cells. Arch Immunol Ther Exp (Warsz) 2004 0.83
118 Expression and regulatory effects of murine Schlafen (Slfn) genes in malignant melanoma and renal cell carcinoma. J Biol Chem 2013 0.83
119 Regulation of leukemic cell differentiation and retinoid-induced gene expression by statins. Mol Cancer Ther 2009 0.83
120 Arsenic trioxide and the phosphoinositide 3-kinase/akt pathway in chronic lymphocytic leukemia. Clin Cancer Res 2010 0.82
121 Regulation of interferon-dependent mRNA translation of target genes. J Interferon Cytokine Res 2014 0.82
122 Signaling via the interferon-alpha receptor in chronic myelogenous leukemia cells. Leuk Lymphoma 2002 0.82
123 Protein kinase C signalling in leukemia. Leuk Lymphoma 2008 0.82
124 Role of the translational repressor 4E-BP1 in the regulation of p21(Waf1/Cip1) expression by retinoids. Biochem Biophys Res Commun 2008 0.81
125 Interferons. Cancer Treat Res 2005 0.81
126 Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia. Cancer Biol Ther 2015 0.80
127 Arsenic trioxide-dependent activation of thousand-and-one amino acid kinase 2 and transforming growth factor-beta-activated kinase 1. Mol Pharmacol 2010 0.80
128 Inhibition of histone deacetylase 6 as a therapeutic strategy for acute lymphocytic leukemia. Leuk Lymphoma 2011 0.80
129 Actinomycosis presenting as an oral ulcer in a neutropenic patient. South Med J 2002 0.80
130 Antiviral effects of interferon-β are enhanced in the absence of the translational suppressor 4E-BP1 in myocarditis induced by Coxsackievirus B3. Antivir Ther 2011 0.80
131 Mnk Kinases in Cytokine Signaling and Regulation of Cytokine Responses. Biomol Concepts 2012 0.79
132 BCR-ABL1-induced leukemogenesis and autophagic targeting by arsenic trioxide. Autophagy 2012 0.79
133 Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanisms. Br J Haematol 2010 0.79
134 Induction of autophagy by dual mTORC1-mTORC2 inhibition in BCR-ABL-expressing leukemic cells. Autophagy 2010 0.78
135 Mnk kinases in cytokine signaling and regulation of cytokine responses. Biomol Concepts 2015 0.78
136 IFN-β-specific signaling via a unique IFNAR1 interaction. Nat Immunol 2013 0.78
137 Prospects for mTOR targeting in adult T cell leukemia. Leuk Lymphoma 2009 0.77
138 Statin-dependent activation of protein kinase Cδ in acute promyelocytic leukemia cells and induction of leukemic cell differentiation. Leuk Lymphoma 2012 0.77
139 A new purpose for an old drug: inhibiting autophagy with clarithromycin. Leuk Lymphoma 2012 0.77
140 Antileukemic properties of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Leuk Lymphoma 2013 0.77
141 STAT activation in malignancies: roles in tumor progression and in the generation of antineoplastic effects of IFNs. J Interferon Cytokine Res 2013 0.77
142 Acute myeloid leukemia: potential for new therapeutic approaches targeting mRNA translation pathways. Int J Hematol Oncol 2013 0.77
143 Targeted therapy of acute myeloid leukemia. Expert Rev Anticancer Ther 2015 0.76
144 BH3 mimetics and multi-kinase inhibition in AML. Blood 2012 0.76
145 Mitogen-activated protein kinase pathways in interferon signaling. Methods Mol Med 2005 0.76
146 Design and synthesis of novel derivatives of all-trans retinoic acid demonstrate the combined importance of acid moiety and conjugated double bonds in its binding to PML-RAR-alpha oncogene in acute promyelocytic leukemia. Leuk Lymphoma 2010 0.76
147 Use of mTOR inhibitors in the treatment of malignancies. Expert Opin Pharmacother 2014 0.76
148 Regulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cells. PLoS One 2013 0.76
149 MTHFR polymorphisms and the development of acute leukemia: does it really matter? Leuk Lymphoma 2006 0.76
150 Overcoming treatment challenges in imatinib-resistant chronic myelogenous leukemia. Leuk Lymphoma 2014 0.75
151 Screening for microRNAs in myelodysplastic syndromes. Leuk Lymphoma 2009 0.75
152 NME1 and NME2 as markers for myeloid leukemias. Leuk Lymphoma 2012 0.75
153 Non-tyrosine kinase inhibitor-targeting of BCR-ABL expressing cells. Leuk Lymphoma 2012 0.75
154 Pediatric acute lymphoblastic leukemia: the missing pieces in risk and survival. Leuk Lymphoma 2014 0.75
155 Correlation between IDH2 mutations and disease status in acute myeloid leukemia. Leuk Lymphoma 2010 0.75
156 Implications of lipocalin 2 expression in acute myeloid leukemia. Leuk Lymphoma 2013 0.75
157 Sphingosine kinase is an attractive target for novel pharmacological interventions in non-Hodgkin lymphomas. Leuk Lymphoma 2008 0.75
158 Coexistence of PML-RARα and BCR-ABL in acute promyelocytic leukemia. Leuk Lymphoma 2013 0.75
159 Tyrosine kinase inhibition in acute myeloid leukemia. Leuk Lymphoma 2013 0.75
160 Predicting resistance to dasatinib therapy for patients with Philadelphia-positive leukemia with prior tyrosine kinase inhibitor failure. Leuk Lymphoma 2015 0.75
161 Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. J Clin Invest 2017 0.75
162 Calreticulin gene mutations in the myeloproliferative neoplasms: Dameshek's other "myelostimulatory" factor. Leuk Lymphoma 2015 0.75
163 Acute lymphoblastic leukemia in a patient with chronic cyanoacrylate exposure. Acta Haematol 2007 0.75
164 Progressive transformation of germinal centers. Report of 2 cases and review of the literature. Acta Haematol 2002 0.75